Cargando…

1964. Microbiological Outcomes With Plazomicin (PLZ) vs. Colistin (CST) in Patients With Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study

BACKGROUND: PLZ is a next-generation aminoglycoside with structural modifications that protect it from aminoglycoside-modifying enzymes (AMEs) and in vitro activity against multidrug-resistant (MDR) Enterobacteriaceae, including aminoglycoside- and carbapenem-resistant strains. In the CARE study, PL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serio, Alisa W, Smith, Alex, Krause, Kevin M, Galani, Irene, Gales, Ana Cristina, Jubb, Adrian, Connolly, Lynn E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253793/ http://dx.doi.org/10.1093/ofid/ofy210.1620

Ejemplares similares

Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales
por: Blanchard, Laurine S., et al.
Publicado: (2022)

Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Serio, Alisa W, et al.
Publicado: (2019)

2060. Comparison of Plazomicin MIC Test Strip and Broth Microdilution MIC Results for 125 Enterobacteriaceae
por: Koeth, Laura, et al.
Publicado: (2018)

Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae
por: Thwaites, M., et al.
Publicado: (2018)

124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
por: Keepers, Tiffany R, et al.
Publicado: (2018)

Assessment of the In Vivo Efficacy of Plazomicin (PLZ) Alone or in Combination with Meropenem (MEM) or Tigecycline (TGC) against Enterobacteriaceae (EB) Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent (I+) Murine Septicemia Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2017)

1345. Comparative Activity of Plazomicin and Other Aminoglycosides Against Enterobacteriaceae Isolates From Various Infection Sources From Hospitalized Patients in the United States
por: Castanheira, Mariana, et al.
Publicado: (2018)

Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
por: Castanheira, Mariana, et al.
Publicado: (2017)

The Borrelia burgdorferi c-di-GMP Binding Receptors, PlzA and PlzB, Are Functionally Distinct
por: Kostick-Dunn, Jessica L., et al.
Publicado: (2018)

249 Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City
por: Olafisoye, Olawole, et al.
Publicado: (2014)

Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
por: Galani, Irene, et al.
Publicado: (2019)

P39 Bloodstream infections (BSI) in tertiary ICU—an update!
por: Patel, Veer M., et al.
Publicado: (2022)

Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
por: Suay-García, Beatriz, et al.
Publicado: (2019)

Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
por: Kuti, Joseph L., et al.
Publicado: (2019)

Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
por: Galani, Irene, et al.
Publicado: (2019)

Cost-effectiveness of carbapenem-resistant Enterobacteriaceae (CRE) surveillance in Maryland
por: Lin, Gary, et al.
Publicado: (2022)

1005. HIV-Associated Bloodstream Infection (BSI): Trends Over 7 Years
por: Hooshmand, Babak, et al.
Publicado: (2018)

38. Predicting stenotrophomonas Maltophilia bloodstream Infections (BSI) in the Hematologic Malignancy Population
por: Karaba, Sara M, et al.
Publicado: (2020)

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)
por: Cai, Bin, et al.
Publicado: (2018)

359 Epidemiology of Carbapenem-Resistant Enterobacteriaceae (CRE) at an Academic Medical Center
por: Leiner, Charles, et al.
Publicado: (2014)

1249. Emergence of Diverse Carbapenem-Resistant Enterobacteriaceae (CRE) in the Dominican Republic
por: Fermin, Rita Rojas, et al.
Publicado: (2018)

Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China
por: Zhang, Rong, et al.
Publicado: (2017)

499. Carbapenem-resistant Enterobacteriaceae (CRE)-associated Infections and Prolonged Colonization among Hospitalized Patients Colonized by CRE
por: Khawcharoenporn, Thana, et al.
Publicado: (2019)

855 Risk Factors for Peripherally Inserted Central Catheter (PICC) Bloodstream Infection (BSI)
por: Kagan, Evgenia, et al.
Publicado: (2014)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
por: Ahmed, Sara, et al.
Publicado: (2018)

14-Year Survey in a Swedish County Reveals a Pronounced Increase in Bloodstream Infections (BSI). Comorbidity - An Independent Risk Factor for Both BSI and Mortality
por: Holmbom, Martin, et al.
Publicado: (2016)

Ursolic acid inhibits colistin efflux and curtails colistin resistant Enterobacteriaceae
por: Sundaramoorthy, Niranjana Sri, et al.
Publicado: (2019)

533. Impact of Different Definitions on Reported Rates of Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Passaretti, Catherine, et al.
Publicado: (2019)

509. The Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) in a Community Hospital Setting
por: Lewis, Sally, et al.
Publicado: (2019)

Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Zhu, Yunying, et al.
Publicado: (2021)

912. Impact of Rapid Identification and Stewardship Intervention on Coagulase-negative Staphylococcus Bloodstream Infection (BSI)
por: Goshorn, Eli S, et al.
Publicado: (2022)

Changing Trends in Antimicrobial Susceptibility Patterns of Bloodstream Infection (BSI) in Secondary Care Hospitals of India
por: Karuna, T, et al.
Publicado: (2023)

Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
por: El-Mahallawy, Hadir A., et al.
Publicado: (2022)

Molecular mechanisms related to colistin resistance in Enterobacteriaceae
por: Aghapour, Zahra, et al.
Publicado: (2019)

Structural basis for plazomicin antibiotic action and resistance
por: Golkar, Tolou, et al.
Publicado: (2021)

2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
por: Lepak, Alexander, et al.
Publicado: (2019)

Removal of Carbapenem-Resistant Enterobacteriaceae (CRE) from Blood by Heparin-Functional Hemoperfusion Media
por: McCrea, Keith, et al.
Publicado: (2014)

Comparison of the Performance of Phenotypic Methods for the Detection of Carbapenem-Resistant Enterobacteriaceae (CRE) in Clinical Practice
por: Zhang, Zhijie, et al.
Publicado: (2022)

Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection
por: Lin, Qun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j76h5r2lodd3kl4lrm9us1anrl